Akari Therapeutics "announced that it has entered into definitive agreements with certain institutional investors and accredited investors. The direct offering includes participation by all members of the Akari Board of Directors, including Chairman Dr. Ray Prudo, as well as Akari President and CEO Rachelle Jacques. Akari is expected to receive gross proceeds of approximately $4 million. The definitive agreements include no warrants. Paulson Investment Company, LLC is acting as the exclusive placement agent in connection with this offering."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AKTX:
- Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering
- Akari announces Poland, U.K. approve new manufacturing process for nomacopan
- Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings
- Akari Therapeutics presents case study from Phase 3 Part A trial of nomacopan
- Akari announces pre-clinical development progress toward IND for GA treatment
